ROIV Stock Price Today (May 2026) — Roivant Sciences Ltd. Analysis & Key Metrics 2026-05-22
Roivant Sciences Ltd. (ROIV) is trading at $29.96, down 2.98% today (as of May 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $35.67 (19.1% upside).
- Volatility remains elevated (57.29% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-77.80% YoY) alongside significant competitive pressures.
ROIV Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Roivant Sciences Ltd. - Historical Price & Volume
Market Cap
Enterprise Value: $16.91B
P/E Ratio
Forward P/E: -24.64
Revenue Growth
Year over Year
Analyst Target
+19.1% upside potential
Key Investor Questions About ROIV
What investors need to know before buying
Based on current market data, ROIV presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 54.84)
- Fundamentals say: Challenging (declining revenue trends)
ROIV's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ROIV investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $108.94M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ROIV stock traded between $10.58 and $30.33—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 57.29% annualized volatility and β=1.14, the stock exhibits moderate correlation to market moves—making ROIV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Roivant (ROIV) Climbs 15% on Swing to Profits
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 10 Stocks With Insane Returns Right Now. Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors took heart from its swing to profitability in the fourth quarter of fiscal year 2026, while positioning portfolios ahead of the launch […]
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.
These Two Biotech Stocks Rocketed — And One Just Broke Out
Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment.
Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ...
Roivant Sciences Ltd (ROIV) strengthens its financial position with a $2.25 billion Moderna settlement and prepares for key drug launches amidst mixed study results.
Roivant (ROIV) Q4 2025 Earnings Transcript
Matthew Gline: Let me just call out the slide numbers. And given the quality of the clinical data we've seen on ACR, I think it's like certainly a thing to speculate on that the overall profile of 1402 is part of what's contributing to our ability to deliver this data.
Roivant Sciences Q4 Earnings Call Highlights
Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d
Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)
On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones
Roivant Sciences has seen only a marginal shift in its modeled fair value, from US$35.67 to US$35.71, keeping the headline price target effectively stable. That small move reflects a tug of war in analyst commentary, with optimism around the US$2.25b Genevant and Arbutus settlement and key brepocitinib milestones set against questions about how much of this is already in the stock. Read on to see how to track these shifting views and what to watch as the Roivant story continues to...
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $29.96. The RSI (14-day) is at 54.8, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $35.67 implies 19.1% upside from current levels. Volatility is high at 57.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is -24.64. Price-to-Book is 4.75. Price-to-Sales is 1535.45. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering ROIV, the consensus price target is $35.67. This represents a 19.1% upside from the current price of $29.96. The range spans from a low target of $29.00 to a high target of $41.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. High volatility (57.3% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-77.8% YoY), indicating potential business headwinds. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $108.94M. The debt-to-equity ratio is 2.19, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 30.66, indicating strong short-term liquidity. The quick ratio is 29.81. The company holds $4.53B in cash and equivalents. Free cash flow is negative at $-334,342,944, which could limit the company's ability to manage debt obligations.